What is ENOV's market cap?

$1.41B, based on the Nov 4 close of $24.42.

Does Enovis pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ENOV is sold short?

11.7M shares, 20.9% of float, as of Oct 15, 2026.

What sector is ENOV in?

Healthcare, in the Orthopedic & Surgical Supplies industry.

NYSE · ENOVHealthcareOrthopedic & Surgical Supplies

Enovis Corporation (ENOV)

$24.42+16.90%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$24.42▼ 22.33% in range

Nov 4, 2025Low $17.43 · High $31.51Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Enovis closed at $24.42 on Nov 4, up 16.90%, 22.5% below its 52-week closing high. Volume of 3.8M shares was 2.55× its 20-day average (well above normal).

Split-adjusted performance: +34.2% over one month, -1.7% over six months, -22.2% over one year.

In the quarter ended Jul 3, 2026, revenue was $582.78M, up 3.2% from a year earlier, with a net margin of -0.2%.

Short interest was 11.7M shares at the Oct 15 settlement, up 10.8% from the prior report (20.9% of float, 8.7 days to cover).

Market cap$1.41B57.7M shares

Revenue · quarter$582.8M+3.2% YoY

Diluted EPS$-0.02—

P/E · TTM—P/S 0.6×

Net margin-0.2%Gross 61.6%

Dividend yieldNone

52-week range17.43 – 31.51−22.5% from high

Volume3.8M2.55× 20-day avg

Volatility · 60d72.5%Annualised

Short % of float20.9%8.7 days to cover

Net cash-$1.27BCash $12.6M

Next earnings—Not scheduled

Split-adjusted performance

1W +11.5%1M +34.2%3M −7.2%6M −1.7%YTD −8.3%1Y −22.2%3Y −45.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Orthopedic & Surgical Supplies

Percentile among 22 companies (100 = best)

6-month momentum40

Revenue growth21

Net margin58

Value (low P/E)—

Size67

Industry medians: 6-month return +1.5%, revenue growth +12.8%, net margin −2.8%, P/E 29.2×.

Short interest

Details →

Shares short11.7M+10.8% vs prior

Days to cover8.7Settled Oct 15

% of float20.9%

Short vol. 10d46.7%of daily volume

Closest peers by size in Orthopedic & Surgical Supplies

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ENOVEnovis	$24.42	+16.90%	−1.7%	+3.2%	−0.2%	—	$1.41B
CDRECadre Holdings	$30.84	−0.71%	0.0%	+31.8%	5.5%	36.6	$1.32B	Compare
ESTAEstablishment Labs Holdings	$66.94	+9.02%	−10.2%	+31.7%	−17.4%	—	$1.99B	Compare
AVRAnteris Technologies Global	$6.12	+9.29%	−4.2%	+63.3%	−2883.4%	—	$596.4M	Compare
SMTISanara MedTech	$32.33	+0.50%	+68.8%	+9.0%	−1.6%	—	$297.0M	Compare
MSAMine Safety Incorporated	$177.60	+2.03%	+2.1%	+14.5%	10.9%	22.6	$6.85B	Compare
INGNInogen	$7.22	+2.85%	+1.5%	+3.0%	−4.0%	—	$191.6M	Compare
ALGNAlign Technology	$164.90	+8.79%	−5.2%	+4.3%	10.3%	28.3	$11.71B	Compare
ZBHZimmer Biomet Holdings	$110.15	+13.49%	+33.0%	+4.8%	9.1%	26.0	$21.01B	Compare

News about Enovis

All news →

Enovis to Host Second Quarter 2026 Results Conference Call on August 6thGlobeNewswire Inc. · Jul 17, 2026Neutral ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?The Motley Fool · May 23, 2026Neutral Enovis to Host First Quarter 2026 Results Conference Call on May 7thGlobeNewswire Inc. · Apr 10, 2026▲ Positive

Quick answers

What does Enovis do?: Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions.
What is ENOV's market cap?: $1.41B, based on the Nov 4 close of $24.42.
Does Enovis pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ENOV is sold short?: 11.7M shares, 20.9% of float, as of Oct 15, 2026.
What sector is ENOV in?: Healthcare, in the Orthopedic & Surgical Supplies industry.

About Enovis

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

HQ: Lewisville, TX7,802 employeesListed May 8, 2008enovis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology